Latest Breaking News On - Destiny lung04 - Page 1 : vimarsana.com

Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2 NSCLC.

Edwards kimTrastuzumab deruxtecanEvolving treatment landscapeFirst line trastuzumab deruxtecanNon small cell lung cancerHer2 nsclcHer2 mutated nsclcHer2 non small cell lung cancerAntibody drug conjugatesT dxdDestiny lung04